Compare Kimberly Clark Corp (KMB) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Novavax Inc — how do they compare? Kimberly Clark Corp trades at $97.59 (market cap $32.51B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Kimberly Clark Corp is far larger — about 17.9× Novavax Inc's market cap, and Kimberly Clark Corp pays a 5.24% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 93 Days and Novavax Inc for 59 Days on average.
| KMB | NVAX | |
|---|---|---|
Market Cap | $32.51B | $1.82B |
Volume | 6,139,913 | 6,198,505 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $12.56 |
52-Week Low | $93.05 | $6.22 |
Typical Hold Time | 93 Days | 59 Days |
Enterprise Value | $38.07B | $1.39B |
Dividend Yield | 5.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $97.74, up 1.31% on the day, with a bearish technical outlook and mixed fundamentals. Recent earnings show a Q2 2026 miss but beats in prior quarters, while revenue declined to $16.45B in 2025. The company maintains a strong dividend yield of over 5% with 54 consecutive years of increases, but cash flow trends raise sustainability questions amid its pending Kenvue acquisition.
KMB offers value with a P/E of 19.32 and analyst consensus target of $117.25, implying 20% upside, but risks include integration challenges from the Kenvue deal, litigation liabilities, and pressured cash flows. The stock's high ROE of 129.43% signals efficient capital use, yet investor sentiment is cautious due to near-term execution hurdles.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
